Tensions between Japan and South Korea come as the U.S. and its trading partners are embroiled in a global trade war.Technologyread more
The one-to-eight stock split would mean the current number of ordinary shares — which stands at 4 billion — will increase to 32 billion. It comes ahead of a reported Hong Kong...Asia Marketsread more
Minutes from the Reserve Bank of Australia's monetary policy meeting in July showed the central bank was ready to adjust interest rates if required.Asia Marketsread more
Current and former Tesla employees working in the company's open-air "tent" factory say they felt pressure to take shortcuts to hit aggressive Model 3 production goals,...Technologyread more
China's fiscal spending increased 10.7% in the first six months from a year earlier, the finance ministry said on Tuesday, underlining the government's bid to support the...China Economyread more
The findings by McKinsey and Company come amid a year-long tariff fight between the U.S. and China, which has spilled into areas such as technology and security.China Economyread more
Microsoft's considerable reach into the corporate world isn't something Slack CEO Stewart Butterfield is very concerned about.Technologyread more
Von der Leyen, one of the longest serving ministers in Germany, has tried to woo European lawmakers over the last two weeks – to convince them she is the right person to...Europe Newsread more
A devastating outbreak of African swine fever that has killed millions of pigs in China is changing attitudes in a country where farm hygiene has often been seen as lax by...Livestockread more
In a closed-door meeting at a Manhattan mansion, executives outlined changes to controversial software that was implicated in two crashes.Aerospace & Defenseread more
President Donald Trump and the RNC are picking up key supporters in the business community who did not back him as a candidate in 2016.2020 Electionsread more
Jim Cramer has been on a mission to find the hottest biotechs of 2015. While reviewing all of the top performers of last year, he has found one that not only doubled in value last year but has a personal mission to find a life-saving cure.
"That's some incredible performance, and I think there could be even more upside here if you're willing to take the risk that's inherent in owning a company this small," Cramer said.
John Crowley is CEO of Amicus Therapeutics, a father and a Navy reservist who fought to raise money to become a biotech entrepreneur. He didn't do this just to make money; he did it in an effort to save his two children from a rare condition called Pompe disease.
Wednesday celebrates the five-year anniversary of the movie "Extraordinary Measures," starring Brendan Frasier and Harrison Ford, which chronicled Crowley's devotion to saving his children's lives.
Pompe is a neuromuscular disease that can ultimately be fatal, even with enzyme replacement therapy. Amicus has a drug in Phase 2 trials that leverages their advanced enzyme replacement chaperone platform.
To find out more, Cramer spoke with Crowley on how his personal passion has fed into the passion of the company culture and stock.
"We got involved in biotech in the late 90s, when two of our children were diagnosed with a rare genetic disease…at the time there was nothing," said Crowley "So we really focused as parents initially on what could we do to help drive science to a cure. That was our initial effort, and that led to the development to a first generation treatment that our kids have been on for more than a decade. It saved their lives."
Amicus is a company that develops treatments for rare orphan diseases that need good medications. Biotechs that specialize in orphan diseases have been on the radar of big biotech recently, such as the acquisition of NPS Pharma by Shire, which indicates to Cramer that these companies could be headed higher in the future.
Read more from Mad Money with Jim Cramer
Cramer Remix: Netflix after the news
Cramer: Fear is back! Selloff ahead
Cramer: Don't fall for negative press
The company is specifically working on treatments for lysosomal storage disorders, a genetic condition. The current standard of care is done with enzyme replacement, and Amicus has a drug that stabilizes the patient's enzymes that naturally occur in the body.
"We are always working in devastating disorders where there are tremendous burdens on the people living with the disease, the family members and the people that care for them. What we want to do is develop these life-saving therapies," Crowley added.